Sanofi
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Sanofi commits €1B to expand insulin production in Beijing
The article discusses the importance of enabling JavaScript for optimal app performance.
Study identifies strategies for racial, ethnic diversity in clinical trials
TIDE-Asthma study achieved diversity goals by enrolling 16% Black/African American, 46% Hispanic, 5% Asian, and 33% other race/ethnicity patients, surpassing targets for Hispanic and Asian groups. Strategies included reaching out to key opinion leaders in diverse communities and selecting sites with high asthma prevalence and access to diverse populations.
Sanofi opens AI-powered $595m facility in Singapore
Sanofi's Modulus facility in Singapore, set to be fully operational by 2026, is its first EVolutive vaccine facility outside France, capable of producing up to four vaccines simultaneously. The facility, part of a €935 million investment plan, aims to shorten production timelines and enhance flexibility, prioritizing sustainability with a net zero commitment by 2045.
Combination Antibody Therapy Strategic Research Report
The global Combination Antibody Therapy market is projected to grow from $178.1B in 2023 to $443B by 2030, driven by cancer prevalence, immunotherapy advancements, and personalized medicine. The report by ResearchAndMarkets.com offers insights into market trends, drivers, and forecasts.
Top 10: Most Read Stories From November 2024
Old Baltimore Pike Apothecary and Smith’s Pharmacy II sue 4 PBMs and GoodRx over price manipulation. Avian influenza A(H5) impacts US dairy and poultry, with 53 human cases in 7 states. Lenacapavir for PrEP shows strong efficacy in phase 3 trial. Ruth Carrico discusses flu vaccination importance. Prescription drugs considered critical infrastructure. DEA to hold hearing on marijuana rescheduling. RA patients show low adherence to Mediterranean diet. Pharmacies and DEA share responsibility under CSA. Supreme Court decisions impact pharmacy industry. Inflation Reduction Act affects pharmacy reimbursement.
Should RSV Vaccination Expand to Younger High-Risk Groups?
FDA expanded approvals for RSV vaccines to high-risk young and middle-age adults, but CDC advisors have not yet recommended them. Physicians consider individual health conditions to determine vaccine benefits, with real-world data guiding decisions. Vaccines show protection in high-risk groups, boosting confidence in their efficacy.
Could science have a new treatment for acne?
Clascoterone, a new acne treatment, is available in the US but not yet in Europe. It targets hormonal causes of acne without significant side effects, but its effectiveness compared to existing treatments is unclear. Cosmo Pharmaceuticals, the producer, is seeking distribution partners globally, citing the pandemic as a delay factor.
AI: A strategic imperative for pharmaceutical supply chains
The 2024 LogiPharma AI Report reveals AI's shift from a 'nice-to-have' to a strategic necessity in pharmaceutical supply chains, with over half of surveyed leaders expecting ROI within 2-3 years. AI optimizes inventory management, enhances cold chain logistics, and drives digital transformation, though data integration remains a challenge. The LogiPharma conference in 2025 will focus on AI's practical applications in the industry.
Ten Companies to Watch in AI Drug Discovery
Niven R. Narain emphasizes that AI investments in drug development require robust data and validation. GEN's A-List highlights 10 AI-based drug discovery leaders, including BPGbio, which focuses on cancer energy generation. Other notable companies include Nvidia and Palantir Technologies, though not on the A-List. The list includes specifics on companies like Anima Biotech, Atomwise, and Nimbus Therapeutics, detailing their AI platforms and drug development progress.
Sanofi opens €558m modular concept manufacturing facility in Singapore
Sanofi opens a €558m modular manufacturing facility in Singapore, offering flexible production for next-gen vaccines and biopharmaceuticals, adaptable to future health needs and pandemics, with full operation expected by mid-2026.
© Copyright 2024. All Rights Reserved by MedPath